Position paper on imatinib mesylate in chronic myeloid leukaemia

Br J Haematol. 2002 Oct;119(1):268-72. doi: 10.1046/j.1365-2141.2002.39201.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Drug Approval
  • Drug Costs
  • Forecasting
  • Humans
  • Imatinib Mesylate
  • Interferon-alpha / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / economics
  • Piperazines / economics
  • Piperazines / therapeutic use*
  • Practice Guidelines as Topic
  • Pyrimidines / economics
  • Pyrimidines / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Treatment Failure

Substances

  • Antineoplastic Agents
  • Benzamides
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate